Cara Therapeutics Inc (CARA) stock has risen 5.04% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CARA stock a score of 55 out of a possible 100.
That rank is mainly influenced by a fundamental score of 67. In addition to the average rating from Wall Street analysts, CARA stock has a mean target price of $26.13. This means analysts expect the stock to climb 58.72% over the next 12 months. CARA's rank also includes a long-term technical score of 64. The short-term technical score for CARA is 34.
CARA has an Overall Score of 55. Find out what this means to you and get the rest of the rankings on CARA!
Cara Therapeutics Inc (CARA) stock has fallen -0.51% while the S&P 500 has risen 0.17% as of 2:28 PM on Thursday, Nov 11. CARA is down -$0.09 from the previous closing price of $16.56 on volume of 332,638 shares. Over the past year the S&P 500 has gained 30.29% while CARA has risen 5.04%. CARA earned $0.44 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 37.46.
Click Here to get the full Stock Report for Cara Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
